Rubrik, Inc. Files to Sell 22,000 Shares Amid Growth
Rubrik, Inc. files to sell 22,000 shares of common stock valued at $2.73 million, as director John Thompson exercises stock options.
Bank of Montreal registers $3.38M callable barrier notes
Bank of Montreal files for $3.38M callable notes linked to major indices, targeting investors seeking contingent interest payments.
Cohen Ariel M. Files Form 144 to Sell Shares of Navan, Inc.
Cohen Ariel M. has filed to sell 8,033 shares of Navan, Inc., indicating a liquidity event for the director and officer of the company.
Bloom Energy Corp reports sale of 8,828 shares in filing
Bloom Energy Corp has filed a Form 144 to sell 8,828 shares of its common stock, indicating ongoing market activity.
Neurocrine Biosciences Director Files to Sell 14,700 Shares
Director George Morrow of Neurocrine Biosciences plans to sell 14,700 shares of common stock, valued at approximately $2.15 million.
JPMorgan Chase Financial Co. unveils new structured notes
JPMorgan Chase Financial Co. LLC has filed a preliminary pricing supplement for new structured investment notes linked to major stock indices.
Kenneth J. West plans to sell shares of Honeywell International
Kenneth J. West has filed to sell 879 shares of Honeywell International Inc. following the vesting of restricted stock units.
BofA Finance LLC announces $2.36 million in new notes
BofA Finance LLC has filed a pricing supplement for $2.36 million in Buffered Auto-Callable Return Notes, fully guaranteed by Bank of America Corporation.
HSBC USA Inc. Offers Callable Contingent Income Notes
HSBC USA Inc. files a pricing supplement for callable contingent income barrier notes, enhancing its financial offerings in the competitive banking sector.
Robinhood officer sells 4,473 shares of common stock
Robinhood's Dara Bazzano sells 4,473 shares of common stock, reflecting ongoing activity within the competitive security brokerage industry.
JPMorgan Chase Financial Co. announces new Medium-Term Notes
JPMorgan Chase Financial Co. LLC is launching Medium-Term Notes linked to Asian indexes, signaling a shift in offerings within the national commercial banking sector.
Citigroup files for new 5-year autocallable securities offering
Citigroup Inc. has filed a preliminary pricing supplement for a new offering of 5-year autocallable contingent coupon securities, diversifying its financial products.
JPMorgan Chase Financial Co. unveils new structured notes
JPMorgan Chase Financial Co. has filed a preliminary pricing supplement for Auto Callable Contingent Interest Notes, indicating a strategic move in structured investments.
Citigroup files preliminary prospectus for new securities
Citigroup Global Markets Holdings Inc. has filed a preliminary prospectus for a new financial product linked to the S&P 500 index, indicating innovation in the sector.
Citigroup files preliminary pricing supplement for new securities
Citigroup Inc. files a preliminary pricing supplement for new securities linked to the S&P 500 index, signaling strategic growth in the commercial banking sector.
Xeris Biopharma officer sells 75,000 shares in Form 144
Xeris Biopharma's Beth Hecht sells 75,000 shares, signaling ongoing executive transactions in the pharmaceutical preparations sector.
LTDR Holdco LLC raises $5.9 million in private offering
LTDR Holdco LLC has completed a private offering, raising $5.9 million from 23 accredited investors, marking a significant milestone for the company.
Bank of Montreal Issues $124,000 in Senior Medium-Term Notes
Bank of Montreal announces issuance of $124,000 in Senior Medium-Term Notes linked to the S&P 500 Futures Excess Return Index, maturing in 2031.
Citigroup Global Markets Files for New Securities Linked to S&P 500
Citigroup Global Markets Holdings Inc. files a preliminary pricing supplement for new securities linked to the S&P 500 Futures, showcasing innovation in financial products.
Klein Lawrence Otto sells 25,000 shares of Oruka Therapeutics
Klein Lawrence Otto sells 25,000 shares of Oruka Therapeutics, valued at $2.42 million, reflecting ongoing activities in the pharmaceutical sector.